Brookline Capital raises Kymera Therapeutics price target on reduced risk
In
Investing.comBy Investing.com10/29/2026, 5:12:54 PM
EXECUTIVE SUMMARY
Brookline Capital raises Kymera Therapeutics price target on reduced risk....
Key Takeaways
- Brookline Capital raises Kymera Therapeutics price target on reduced risk.
Read Complete Original Article
Published originally on Investing.com
Related News
finance9 minutes ago
US shipper costs hit five-year high, even as demand stalls, US Bank data shows
US shipper costs hit five-year high, even as demand stalls, US Bank data shows....
finance14 minutes ago
OpenAI says human intent at center of updated AI model guidelines
OpenAI says human intent at center of updated AI model guidelines....
finance15 minutes ago
Trump says Canada has been treating the US very nicely
Trump says Canada has been treating the US very nicely....
finance18 minutes ago
Why is Hyperliquid Strategies stock surging today?
Why is Hyperliquid Strategies stock surging today?....
Multikhabar App
All Information In One Place
Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!